CDXS.NASDAQCodexis, INC

SCHEDULE: Millennium Management Discloses Stake in Codexis

Sentiment:

Schedule 13G Filing


Millennium Management LLC and affiliated entities have reported beneficial ownership of 5.2% of Codexis, Inc. common stock.

Summary

  • Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G.
  • The filing indicates beneficial ownership of 4,734,627 shares of Codexis, Inc. common stock.
  • This represents 5.2% of the class of securities.
  • The reporting persons are based in Delaware, with Israel A. Englander being a U.S. citizen.
  • The filing confirms that the securities were not acquired or held for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of beneficial ownership by a large investment firm and does not inherently signal positive or negative performance for the company.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Management Comments

  • The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC).
  • The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by Millennium Management and its affiliates indicates a significant passive investment in Codexis, Inc., a biotechnology company focused on enzyme engineering. Such filings often signal a substantial institutional interest, though not necessarily an intent to control or influence management.

Stakeholder Impact

  • Shareholders: The filing indicates increased institutional interest from a major investment firm, which could be perceived positively by the market, though the passive nature of the filing suggests no immediate intent to influence company strategy.
  • Management: The filing confirms that the reporting persons do not intend to influence or control the issuer, which may provide some reassurance to current management.
  • Creditors: No direct impact on creditors is indicated by this filing.

Key Dates

DateDescription
2026-04-09Date of Event Which Requires Filing of this Statement
2026-04-13Date of Joint Filing Agreement and Signatures

Keywords

Codexis, Schedule 13G, Millennium Management, Integrated Core Strategies, Beneficial Ownership, Securities Filing, Investment Management

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.